Marker Therapeutics

What Marker Therapeutics does

Marker Therapeutics, Inc. (NASDAQ: MRKR) is a clinical-stage biopharmaceutical company headquartered in Houston, Texas that develops non-genetically modified, multi-antigen recognizing T cell (MAR-T) immunotherapies for blood cancers and solid tumors. The company's proprietary platform — exclusively licensed from Baylor College of Medicine — selectively expands a patient's natural tumor-specific T cells from a standard blood draw, producing a product that recognizes hundreds of epitopes across up to six tumor-associated antigens (Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, WT-1), thereby addressing tumor heterogeneity and reducing the risk of antigen-escape relapse that limits single-target CAR-T therapies.

The pipeline is anchored by MT-601, currently in the Phase 1 APOLLO multi-center study for non-Hodgkin lymphoma patients who have relapsed or are ineligible for anti-CD19 CAR-T therapy, and MT-401 in the Phase 2b ARTEMIS trial for post-transplant acute myeloid leukemia (AML), with MT-401-OTS extending the AML franchise into off-the-shelf dosing. A company-sponsored Phase 1 program in pancreatic cancer is planned for the first half of 2026 following published Baylor data showing an 84.6% disease control rate.

The business is clinical-stage with no commercial products; reported Q4 2025 revenue of approximately $1.10M derives from collaborations and grants rather than product sales, and the company posted a $12.2M net loss for full-year 2025 with $17M in cash and equivalents at year-end. Marker has secured more than $19M in non-dilutive grant funding from CPRIT, the NIH (SBIR), and the FDA, supplemented by a $25M stock purchase agreement with Lincoln Park Capital Fund (December 2022). As of March 2026 the company's market capitalization stood at roughly $22.34M. Customers today are patients enrolled in investigator-initiated and company-sponsored trials at multiple US centers; payer and provider relationships will only form upon potential regulatory approval.

Name

Marker Therapeutics

Legal name

Marker Therapeutics, Inc.

Website

https://markertherapeutics.com

Company type

Public

Founded year

1992

Operating status

Operating

Headcount range

11–50 employees

Short description

Marker Therapeutics is a clinical-stage biopharmaceutical company developing non-genetically modified, multi-antigen recognizing T cell (MAR-T) immunotherapies for relapsed lymphoma, AML, and pancreatic cancer, with no commercial product and revenue sourced primarily from grants.

Ownership category

akta.pro rank

Product category

Cell Therapy / T Cell Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• T cell immunotherapy
• Cell therapy platform
• Multi-antigen therapy
• Clinical-stage biopharmaceutical
• Adoptive cell therapy

Headquarters

HQ city

Minneapolis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pre-Revenue / Clinical Stage: Marker Therapeutics is a clinical-stage biopharmaceutical company with no commercially approved products. The company is developing T cell-based immunotherapies and has not yet generated product revenue. Current financial results show quarterly revenue of approximately $1 million primarily from collaborations or grants, with significant net losses ($12.2 million for 2025).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Marker Therapeutics develops clinical-stage, non-genetically engineered, multi-antigen T cell therapies (MAR-T cells) that selectively expand natural tumor-specific T cells from a patient's blood to recognize multiple tumor antigens. Its lead product MT-601 targets six tumor antigens (Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, WT-1) and is being evaluated in Phase 1 trials for relapsed non-Hodgkin lymphoma and pancreatic cancer. The pipeline also includes MT-401 and its off-the-shelf variant MT-401-OTS for AML.

Product overview

Marker Therapeutics is a clinical-stage biopharmaceutical company developing T cell-based immunotherapies using its proprietary MAR-T (Multi-Antigen Recognizing T cell) technology platform. The platform enables selective expansion of natural tumor-specific T cells that recognize multiple antigens without genetic modification. The core product portfolio includes MT-601 (lead candidate for lymphoma), MT-401 (for AML with both personalized and off-the-shelf versions), targeting various tumor-associated antigens including Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, and WT-1.

Differentiator

Problem solved

Functional benefit

Products and services

• MT-601 Lead product candidate, a multi-tumor associated antigen-specific T cell product recognizing six tumor antigens (Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, WT-1) currently evaluated in a Phase 1 APOLLO study for lymphoma patients who relapsed or are ineligible for anti-CD19 CAR-T therapy.
• MT-401 Multi-tumor associated antigen-specific T cell product for Acute Myeloid Leukemia (AML), targeting post-transplant minimal residual disease, being evaluated in Phase 2b ARTEMIS trial in combination with hypomethylating agents.
• MT-401-OTS Off-the-shelf version of MT-401 T cell product for AML treatment, with first patient treated in Q3 2025 as part of the company's off-the-shelf program.
• MAR-T Cell Technology Platform Multi-Antigen Recognizing T cell technology platform that selectively expands natural tumor-specific T cells from patient blood, capable of recognizing hundreds of epitopes within up to six tumor-associated antigens without genetic modification.

Quantifiable outcome

• 66% objective response rate (ORR) in relapsed non-Hodgkin lymphoma patients including 50% complete responses
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Baylor College of MedicinecoreStrategic or Co-development Partner · 5 January 2026Baylor College of Medicine developed the MAR-T cell technology and published promising Phase 1/2 clinical trial results in Nature Medicine. Marker Therapeutics holds worldwide exclusive license for the T cell technology. Baylor is conducting pancreatic cancer research with Marker planning to initiate its own program.
• Cellipont BioservicescoreTechnology or Integration · 1 January 2025Manufacturing collaboration with Cellipont Bioservices for the production of Marker Therapeutics' T cell therapy products. This partnership supports the company's manufacturing capabilities as it advances its clinical programs.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Iovance Biotherapeutics: Clinical and commercial-stage cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors and hematologic malignancies; directly comparable to Marker as a publicly traded cell therapy developer with overlapping hematology and oncology targets.
• Adaptimmune Therapeutics: Developer of engineered TCR-T cell therapies (Tecelra) targeting solid tumor antigens including NY-ESO-1, MAGE-A4; comparable to Marker's multi-antigen T cell strategy and similar clinical-stage commercial profile.
• Allogene Therapeutics: Allogeneic CAR-T developer with off-the-shelf platform targeting hematologic malignancies, directly relevant given Marker's MT-401-OTS off-the-shelf T cell program and shared CD19-targeting competition.
• Atara Biotherapeutics: Allogeneic T cell therapy developer (Tabelecleucel/EBVALLO) for post-HSCT lymphoproliferative disease; overlaps with Marker in cell therapy targeting hematologic malignancies and pursuing off-the-shelf T cell approaches.
• Cellectis: Clinical-stage cell therapy company developing allogeneic CAR-T (UCART) products using TALEN gene editing; comparable as a publicly traded cell therapy peer pursuing hematologic indications with off-the-shelf approaches.
• Precision BioSciences: Developer of in vivo and ex vivo gene-edited cell therapies (ARCUS platform) targeting hematologic malignancies and solid tumors; comparable clinical-stage cell therapy peer with overlapping oncology focus.

Broad incumbents

• Adaptimmune (SPEAR T-cells) vs. CAR-T players — Bristol Myers Squibb: BMS markets Breyanzi and Abecma CD19/BCMA CAR-T therapies directly competing with MT-601 in relapsed/refractory NHL and multiple myeloma; represents the incumbent standard-of-care that Marker's MAR-T must displace or follow.
• Gilead (Kite Pharma): Kite (Gilead) markets Yescarta and Tecartus CD19 CAR-T therapies, the established benchmark that Marker Therapeutics' MT-601 must compare against in the anti-CD19 CAR-T relapsed NHL setting.

Emerging players

• Cargo Therapeutics: Emerging cell therapy developer focused on engineered CAR-T approaches for hematologic malignancies including LBCL; relevant as a recent IPO-stage peer competing for the same anti-CD19 relapsed NHL space MT-601 targets.
• Caribou Biosciences: Clinical-stage allogeneic CAR-T developer (CB-010, CB-012) using CRISPR gene editing; comparable peer as a smaller publicly traded cell therapy company pursuing hematology indications and off-the-shelf platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/marker-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds11 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marker Therapeutics